PHARMACEUTICAL IP

  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our Offering
    • Fractional in-house
    • Start-ups
    • Established pharma
    • International IP counsel
    • Investors
    • Due diligence
    • Evolve AI
  • Fractional in-house
  • Sectors
    • Pharmaceuticals
    • Biotechnology
    • Biologics
    • Cell & gene therapies
    • AI drug discovery
    • Chemistry
  • Evolve Insights
    • Articles
    • Events & Webinars
    • Subscribe
  • About us
    • Our team
    • Join us
    • Contact us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us
  • Our offering
  • Fractional in-house
  • Sectors
  • Evolve Insights
  • Our team
  • Join us

Boeing’s comma drama: Commas and taking the description into account when construing a claim (T 1127/16)

  • Sector: Patent law
  • 30th May 2021
It is not only the choice of words that matter in patent claim interpretation. As the recent decision in T 1127/16 shows, grammar can be similarly important.  
 

Originally posted on IPKat.

In this decision, the lack of a comma in a claim led to a successful added matter objection against Boeing’s patent EP1798872. Caught in the inescapable trap of added matter that cannot be deleted without unallowably broadening the claim, the patent was found invalid on appeal. However, aside from the obvious lesson to be scrupulous in your claim drafting, the decision in T 1127/16 is also worth a read for the Board of Appeal’s comments on the primacy of the claims over the description for determining the scope of protection. 

The importance of commas

The patent in question (EP1798872) in T 1127/16 related to a method of handling communications between a ground-based computer and an aircraft. The granted claim specified a process for selecting a preferred transmission network for the communication. The absence of a comma in one of the features meant that the step could be interpreted two ways. The ambiguity caused by the lack of comma is a classic linguistic peculiarity of English grammar (and also recently ignited yet further Brexit-related debate). In this case, a comma was needed to delineate a subordinate clause, a related but not identical issue to the use of Oxford commas. 

In the case in question in T 1127/16, one feature of the method claim comprised the provision of a list. The subsequent feature in the claim was not separated from the list step by a comma. The subsequent feature could thus be construed as either forming part of the provided list, or as forming a second independent step. Given the absence of the comma, the Opposition Division (OD) construed the claim as requiring the features to be run together. Since the OD found no disclosure of this combined feature in the application as filed, the patent was found invalid for added matter (Article 123(2) EPC). 

The Board noted that English does not have clear rules governing the use of commas. However, the Board determined that if the patentee had intended the relevant features to be separated, a comma would have been necessary in order to “even suggest” the separation to the reader (r. 2.6.4).

The Board of Appeal further found that a skilled person could not be expected to “speculate as to other possible meanings which might result from inserting commas at various places”, as this would place undue burden on the reader. Looking solely at the claim language, therefore, the Board of Appeal agreed with the OD that the claim should be construed as requiring the features to be run together. 

The claims, not the description, define the scope of protection

On appeal, the patentee argued that a skilled person reading the claim would consult the description in order to resolve the linguistic ambiguity in the claim. In doing so, the patentee argued, it would become clear to the skilled person that the method comprised identifying the most preferred network available as a separate step.

The Board of Appeal was not convinced by the patentee’s arguments. The Board noted the often quoted T 190/99, according to which a “patent must be construed by a mind willing to understand not a mind desirous of misunderstanding” (Case Law of the Boards of Appeal II.A.6.1). However, the Board did not consider the case law as requiring consultation of the description as soon as any ambiguous feature occurs in the claim (r. 2.6.1):

“According to such a logic, an applicant (patent proprietor) could then arguably dispense with providing a clear and unambiguous formulation of claim features, e.g. during the grant proceedings, in order to be able to fall back on a more description-based interpretation at will during a subsequent opposition proceedings”

The Board of Appeal thus confirmed that a claim should essentially be read and interpreted on its own merits: 

“… the description cannot be used to give a different meaning to a claim feature which in itself imparts a clear, credible technical teaching to the skilled reader […] Otherwise third parties could not rely on what a claim actually states“.

In the case in question, the Board of Appeal thus considered the pertinent question as being whether the claimed feature was meaningful and plausible from a technical point of view. In finding no technical reason for the claimed feature not to make technical sense, the Board of Appeal agreed with the OD that the claims was invalid for added matter (Article 123(2) EPC). The Board further rejected auxiliary requests in which the claims were amended to remove the possibility of the unwanted interpretation. However, these requests were rejected as broadening amendments, and thus not permitted post-grant (the “inescapable-trap”). 

Final thoughts

The contents of the description can be influential in questions of infringement. In the recent High Court case Illumina v MGI ([2021] EWHC 57 (Pat)), Mr Justice Birss (as he then was) found lack of infringement by equivalence in view of a strict definition of a term in the claim provided in the description. Mr Justice Birss observed in Illumina v MGI that a limiting definition of a feature in the description, limits the scope of the claim. This observation appears at odds with the EPO case law, according to which the claims should be read on their own merits.  The decision of the Board in T 1127/16 makes it clear that the description cannot be used to give a different meaning to claim language that is prima facie clear. The Board’s statement that “otherwise third parties could not rely on what a claim actually states” is one of the main objections lodged against the broad doctrine of equivalents adopted by UK judges. 

Related insights...

G 1/25 (description amendments) amicus curiae: The battle lines are drawn

  • 4th March 2026
If you want to start an argument amongst European patent attorneys, just mention description amendments. As the comments on this and other blogs attest, adaptation of the description is a highly divisive issue and the debate can get decidedly heated (with our US colleagues looking on with bemusement).

Mechanistic insights supporting the sufficiency and inventive step of a therapeutic use (without clinical data) (T 1601/22)

  • 24th February 2026
At the EPO, it is perfectly possible for a therapeutic invention to survive without clinical data. The recent decision in T 1601/22 confirmed this sometimes surprisingly low bar for sufficiency in Europe for therapeutic invention.

Non-reproducible products can be the closest prior art (T 1719/21)

  • 17th February 2026
G 1/23 establishes that products made available to the public are prior art in Europe, regardless of reproducibility. While this simplifies novelty, focusing strictly on disclosure dates, it complicates inventive step assessments. Notably, T 1719/21 questions whether these non-reproducible products can serve as the “closest prior art” in the EPO’s problem-solution approach.

ViCo oral proceedings: Whatever happened to the in-person “Gold-Standard”?

  • 14th December 2025
We are now many years on from the pandemic conditions that initially led to the introduction of oral proceedings by video conferencing for Board of Appeal cases. But what happened to the “Gold Standard” of in-person proceedings promised by the EBA in G 1/21? 

EPO pharma case law trends 2025: Clinical inventions

  • 26th November 2025
The law in the pharma sector field is also constantly evolving. Understanding the case law trends when drafting, prosecuting and defending these cases is therefore paramount. In our second post on EPO pharma case law trends in 2025 (see Evolve Insights), we review the most impactful decisions of the year relating to clinical-stage inventions. 

EPO pharma case law trends 2025: Antibodies and biologics

  • 19th November 2025
The science of biologics is rapidly progressing, with the development of ever more complex protein structures, incorporation of molecules into cell therapies and the increasing use of AI-assisted design and in silico modelling. Patent law must respond to these new challenges. What better time to take a look at the trends from the EPO case…

Insufficiency resulting from mutually exclusive definitions: The repercussive effect of dependent claims (T 0878/23)

  • 18th November 2025
In T 0878/23, the Board of Appeal ruled that mutually exclusive ranges in dependent claims constitute fatal insufficiency rather than a mere lack of clarity. This decision underscores the “repercussive effect” of claim dependencies, warning that internal contradictions can make an invention technically impossible to perform.

First use of G 1/24 to broaden clear claim language (T 1849/23)

  • 16th November 2025
This significant decision is the first from the Boards of Appeal to apply G 1/24 to the use of information from the description to broaden otherwise clear claim language.

Sufficiency at the priority date: A study protocol is not “the same” as a therapeutic effect invention (T0883/23)

  • 31st October 2025
Therapeutic inventions are generally not considered sufficiently disclosed absent supporting data. The recent decision in T 0883/23 found that this applies both at the priority date and the filing date of the patent.

Patentee’s own post-published data undermines the credibility of their broad cat antibody patent (T 0709/23)

  • 27th October 2025
How early is too early to file a biotech patent? EPO decision T 0709/23 provides a costly answer, demonstrating the fatal risks of claiming a broad therapeutic use before the link between structure, function, and actual effect is truly understood.
All Insights

evolve® is a trading entity of Evolve Intellectual Property Limited. Evolve Intellectual Property Limited is regulated by the Intellectual Property Regulation Board (IPReg). Details of the UK professional rules can be found on the IPReg website

registered address: 49 Greek Street, London, England, W1D 4EG

website out of house

© 2026 All Rights Reserved

Keep in touch

Subscribe

Contact Us